![](https://endpts.com/wp-content/uploads/2024/04/GettyImages-2113284075-scaled.jpg)
Rob Davis, Merck CEO (Jeenah Moon/Bloomberg via Getty Images)
Merck returns to lucrative eye disease market in up to $3B deal for EyeBio
A decade after departing the ophthalmology drug market, Merck is launching a return to the field in a $1.3 billion upfront cash acquisition for Series …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.